Industry Symposium by AstraZeneca

IND 20 - Systemic anti‑cancer therapy (SACT)-related ILD/pneumonitis in breast cancer patients

This symposium intends to educate the audience on SACT–related ILD/pneumonitis in breast cancer patients, including its clinical and radiological manifestations, in order to improve early identification, monitoring and management. The session will highlight the importance of collaboration within an MDT for prompt identification and management, as well as deep dive into radiological patterns which may be indicative of SACT–related ILD/pneumonitis. Learnings will be put into practice through discussion of two clinical cases, followed by a Q&A session.
5 min
Welcome and introduction
Julien Dinkel, Munich / Germany
Nikolaus Kneidinger, München / Germany
15 min
Overview of systemic anti–cancer therapy (SACT)-related ILD/pneumonitis in breast cancer patients
Nikolaus Kneidinger, München / Germany
Learning Objectives

  1. Describe and define SACT–related ILD/pneumonitis

  2. Analyse SACT–related ILD/pneumonitis symptoms and risk factors

  3. Identify breast cancer SACTs with associated risk of ILD/pneumonitis

  4. Review and evaluate SACT–related ILD/pneumonitis diagnostic and treatment algorithms

10 min
Radiologist's role in optimising patient care for SACT-related ILD/pneumonitis
Julien Dinkel, Munich / Germany
Learning Objectives

  1. Consider and describe the radiologist's role in early identification of SACT–related ILD/pneumonitis

  2. Identify key radiological features of ILD/pneumonitis and integrate knowledge in order to diagnose presymptomatic ILD/pneumonitis cases

  3. Summarise the importance of early ILD/pneumonits identification, diagnosis and management

  4. Discuss the importance of an MDT approach and exemplify collaborative care with the patient

15 min
SACT-related ILD/pneumonitis in clinical practice
Julien Dinkel, Munich / Germany
Nikolaus Kneidinger, München / Germany
Learning Objectives
Describe optimal pneumonitis identification and management strategies through a clinical case-based discussion
10 min
Q&A
Julien Dinkel, Munich / Germany
Nikolaus Kneidinger, München / Germany
Learning Objectives
Assess levels of understanding and provide an opportunity to ask questions to address any remaining gaps in SACT-related ILD/pneumonitis knowledge
5 min
Meeting summary and close
Julien Dinkel, Munich / Germany
Nikolaus Kneidinger, München / Germany

Lectures

1
Welcome and introduction

Welcome and introduction

05:00Julien Dinkel, Munich / DE, Nikolaus Kneidinger, München / DE

2
Overview of systemic anti-cancer therapy (SACT)-related ILD/pneumonitis in breast cancer patients

Overview of systemic anti-cancer therapy (SACT)-related ILD/pneumonitis in breast cancer patients

15:00Nikolaus Kneidinger, München / DE

3
Radiologist's role in optimising patient care for SACT-related ILD/pneumonitis

Radiologist's role in optimising patient care for SACT-related ILD/pneumonitis

10:00Julien Dinkel, Munich / DE

4
SACT-related ILD/pneumonitis in clinical practice

SACT-related ILD/pneumonitis in clinical practice

15:00Julien Dinkel, Munich / DE, Nikolaus Kneidinger, München / DE

5
Q&A

Q&A

10:00Julien Dinkel, Munich / DE, Nikolaus Kneidinger, München / DE